Cleanroom manufacturing is fast becoming the backbone of Australia’s high-tech economy, fuelling growth across pharmaceuticals, biotechnology, MedTech, and even space exploration. According to Horizon Grand View Research, Australia’s cleanroom technology market is forecast to reach US$181.4 million by 2030, expanding at a 6% CAGR between 2025 and 2030. This steady growth underscores the pivotal role cleanroom facilities play in enabling innovation, ensuring product quality, and meeting stringent regulatory standards across advanced industries.

In Brisbane, the Translational Research Institute (TRI), in collaboration with the Queensland Government, is investing $100 million in the Translational Manufacturing Facility (TM@TRI). Scheduled to open in early 2026, it will be the nation’s first on-demand cGMP cleanroom facility, designed to support high-potential biotech, pharmaceutical, and MedTech companies in accelerating innovation and scaling production. At the same time, Pfizer is advancing its cleanroom capabilities with AU$150 million (US$98 million) expansion of its Melbourne site. The project includes the addition of two 40 m² freeze-drying fridges (lyophilizers) to increase production of antimicrobial treatments for hospitalized patients with serious infections. Together, these investments highlight Australia’s growing commitment to strengthening its cleanroom infrastructure and positioning the nation as a hub for advanced pharmaceutical and biotech manufacturing.

In biotechnology, Cartherics has launched a state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products. With the global cell therapy market expected to surpass $60 billion by 2032, the company is strategically positioned to leverage cleanroom-enabled manufacturing for the scalable production of off-the-shelf immune stem cell therapies, initially targeting ovarian cancer and endometriosis.

The Cleanroom Manufacturing conference by Trueventus offers the ultimate platform for professionals driving innovation in cleanroom technology and manufacturing practices. This event convenes industry leaders and experts to share practical insights, case studies, and best practices in contamination control, facility optimization, and regulatory compliance. Attendees will also explore emerging solutions—from modular cleanrooms and advanced air filtration systems to automation technologies—while networking with the key stakeholders shaping the future of sterile and cleanroom manufacturing.

AM360 Pty Ltd is an Australian supplier and installer of high-performance hygienic wall systems for cleanroom, pharmaceutical, medical manufacturing, and controlled-environment facilities.

Our flagship product, AM-Clad, is an antimicrobial PVC wall cladding system engineered for environments where hygiene, durability, and compliance are critical. AM-Clad incorporates silver-ion antimicrobial technology that provides continuous surface protection, helping to reduce microbial load between cleaning cycles.

AM-Clad is non-porous, impact-resistant, and chemically resilient, making it suitable for cleanrooms, laboratories, compounding rooms, and high-care production spaces. The system is compatible with VHP (Vapourised Hydrogen Peroxide) decontamination regimes, as well as routine neutral detergent and chlorine-based cleaning protocols commonly used in regulated facilities.

With Group 1 fire performance achieved through full-room burn testing, and seamless welded installation options, AM-Clad provides a compliant alternative to traditional tiled or painted wall finishes. Delivering fast installation, easy maintenance, and long-term performance in hygiene-critical environments.

AM360 works closely with designers, engineers, builders, and facility managers to support cleanroom and controlled-environment projects across healthcare, pharmaceutical, biotechnology, and advanced manufacturing sectors.